Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market

Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Access Here

Additional indications potentially double the addressable market beyond pancreatic cancer pain

Follow-on expansion phase expected to begin in Q2 2025

THE WOODLANDS, TX, May 13, 2025 (GLOBE NEWSWIRE) -- – Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today reiterated its plans for a follow-on phase to its proof-of-concept human clinical trial (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. Additionally, the Company announced the release of a Virtual Investor CEO Connect segment discussing the PoC 2 phase. Access the segment here.

As previously announced, based on the positive results demonstrated in the initial phase of the Company’s first-in-human proof-of-concept trial (“PoC 1”) in patients with severe pancreatic cancer pain, Autonomix will initiate the follow-on PoC 2 phase in a market expansion opportunity which has the potential to double the addressable market beyond pancreatic cancer pain by evaluating additional visceral cancers that signal pain through the Celiac Plexus and earlier stage pancreatic cancers with moderate to severe pain. The Company’s PoC 2 phase is on track to commence in the second quarter of 2025.

“We are thrilled with the compelling results of our PoC 1 phase in late-stage pancreatic cancer patients, which demonstrated a significant reduction in pain, substantially decreased opioid use, and showed a meaningful improvement in quality of life for these patients. Building on this success, we are expanding our investigation to include gall bladder, liver, and bile duct cancers— effectively doubling our addressable potential market. This strategic expansion highlights the broad potential of our smart catheter technology and reinforces our commitment to transforming care for patients worldwide,” Brad Hauser, CEO of Autonomix commented.